DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...
GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and ...
As the diagnostic industry evolves under new regulations and advancing technologies, outsourcing production has become vital to maintain innovation and speed. Yet, identifying the right manufacturing ...
On April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs).[1] The rule explicitly categorizes in vitro diagnostic products (IVDs) intended for clinical use ...
Next-generation molecular diagnostics are transforming disease detection, monitoring, and treatment strategies, propelling us into a new era of precision medicine. Whether identifying clinically ...
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows “Accurate diagnosis, including ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results